KLK3 and prostate adenocarcinoma: In a clinical study in patients with metastasized adenocarcinoma of the prostate, docetaxel (75 mg/m2 every 3 weeks) monotherapy was compared to combined treatment of docetaxel with DCs transfected with mRNAs encoding PAP (prostate acidic phosphatase) and PSA (prostate-specific antigen).64